How to Read and Trade AI Powered Stock Charts
Enter Stock Symbol to View AI powered Stock Chart
StockChartsAI.com
All Chart Prices as of Previous Day CloseBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
12/07/2023 16:00:00 EST
Ultragenyx (RARE)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 30 trading days, RARE has been trading in a range between $39.97 and $31.73 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
RARE is trading between resistance at $46.43 about 12% to the upside and support at $40.16 -3% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $52.15, about a 26% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Ultragenyx (RARE) entered a Green zone 17 days ago on the AI powered stock chart. Wall Street analysts have a recent rating of 4.526, which is a Strong Buy. The current analyst target price is $90.56, which gives it a potential upside of 118.64 % from the recent price of 41.42. The stock is trading 32.74% (potential upside) below its 52 week high of $54.98 and 31.41 % (potential downside) above its 52 week low of $31.52 - based on the recent price.
Company Summary
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
News
| Ultragenyx to Participate at Investor Conferences in November 6 th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that management, will participating in two upcoming investor conferences. Source: GlobeNewsWire Mon, 20 Nov 2023 16:30:00 -0500 Sentiment: Neutral |
| Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 22,765 restricted stock units of the company's common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2023, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4). Source: GlobeNewsWire Fri, 17 Nov 2023 16:30:00 -0500 Sentiment: Neutral |
| Ultragenyx to Participate in the Jefferies London Healthcare Conference NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 12:30 p.m. GMT. Source: GlobeNewsWire Tue, 07 Nov 2023 17:00:00 -0500 Sentiment: Neutral |
| Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook. Source: Zacks Investment Research Fri, 03 Nov 2023 12:47:05 -0400 Sentiment: Negative |
| Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q3 2023 Earnings Conference Call November 2, 2023 5:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris - Chief Commercial Officer Howard Horn - Chief Financial Officer Eric Crombez - Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Dae Gon Ha - Stifel Michael Riad - Morgan Stanley Tazeen Ahmad - Bank of America Kristen Kluska - Cantor Fitzgerald Maury Raycroft - Jefferies Yaron Werber - TD Cowen Laura Chico - Wedbush. Operator Good afternoon, and welcome to the Ultragenyx Third Quarter 2023 Financial Results Conference Call. Source: Seeking Alpha Thu, 02 Nov 2023 22:29:10 -0400 Sentiment: Neutral |
Technicals 52 Week Hi: 54.98 52 Week Low: 31.52 Beta: 0.73 50 Day MA: 36.4454 200 Day MA: 41.1809 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.081 Forward PE: 0 Trailing PE: 0